Abstract
557 Background: Combining non-cross resistant agents is the mainstay of cancer treatment. The question is whether evaluate combining a small molecule ErbB1/ErbB2 kinase inhibitor with anti-ErbB2 an...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
